Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Clin Cancer Res. 2021 Sep 15;27(23):6405–6412. doi: 10.1158/1078-0432.CCR-21-1579

Figure 2. The majority of patients developed intra- and/or intermolecular epitope spreading after IGFBP-2 N-terminus vaccination.

Figure 2.

(A) Mean (±SEM) percent T-cell clonality. Mean (±SEM) corrected IFN-γ spots per well (cSPW) in 1x106 PBMC stimulated with (B) the C-terminal epitopes of IGFBP-2 or (C) IGF-IR epitopes. Connected points represent the response determined pre-treatment (0) and at the maximum response (Max) generated for each patient. *p<0.05.